In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic and MiniMed: Stuck on the Balance Sheet

Executive Summary

MiniMed's growth rate has been slipping down through the teens for some time: the introduction of long-acting basal insulin is slowing growth of its core insulin pump business, and development of a continuous glucose monitoring system has seemingly slowed to a snail's pace. And the dynamic growth opportunity envisioned two years ago, when Medtronic bought MiniMed, is now impinging on the parent corporation's balance sheet.
Advertisement

Related Content

Continuous Glucose Monitoring: A Revolution Powered by DexCom
Keeping Leadership Real: An Interview with Bill George
Becton Dickinson, with Heavyweight Helpers, Finally Jumps into Diabetes Testing
Becton Dickinson, with Heavyweight Helpers, Finally Jumps into Diabetes Testing
TheraSense's Sweet Spot
TheraSense's Sweet Spot
Tyco Buys Bard, While Medtronic Scoops Up MiniMed

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel